** Shares of drugmaker Abeona Therapeutics ABEO.O rise 2.07% to $4.67

** Co says it has added NewYork-Presbyterian/Columbia University Irving Medical Center as a treatment center for its gene therapy, Zevaskyn, expanding access in New York and the Northeast

** Says the site is its fifth qualified treatment center

** Zevaskyn is the only gene therapy approved for wounds in adults and children with recessive dystrophic epidermolysis bullosa, a rare inherited skin disease that causes severe blistering and hard-to-heal wounds - ABEO

** Says the treatment uses a patient's own skin cells, modified to restore the missing type VII collagen needed to hold skin layers together

** ABEO shares were down over 5% in 2025